Document:

ex10_1.htm

    Exhibit
10.1

    

    Before
the Public Service Commission

    Of
the State of Missouri

    

    
      
        
          	
                  In
      the Matter of the Tariff Filing of KCP&L Greater Missouri Operations
      Company, to Implement a General Rate Increase for Retail Electric Service
      Provided to Customers in its Missouri Service Areas it formerly served as
      Aquila Networks—MPS and Aquila Networks—L&P.

                   

                	
                  )

                  )

                  )

                	
                  Case No.
      ER-2009-0090

                  Tariff
      No. JE-2009-0913

                

        

      

    

    

    NON-UNANIMOUS STIPULATION
AND AGREEMENT

    

    

    COME NOW the undersigned—KCP&L
Greater Missouri Operations Company (“GMO”), the Staff of the Missouri Public
Service Commission (“Staff”), the Office of the Public Counsel (“OPC”), Missouri
Department of Natural Resources (“MDNR”) and Dogwood Energy, LLC (“Dogwood”)
(individually “Signatory” and collectively “Signatories”) and state the
following for this Non-unanimous Stipulation and Agreement (“2009 GMO
Stipulation”).  The terms “Non-Utility Signatory” and “Non-Utility
Signatories” refers to a party other than GMO that has signed this 2009 GMO
Stipulation and all of the parties other than GMO that have signed this 2009 GMO
Stipulation, respectively.

     

    1.           Revenue
Requirement

     

    The Signatories agree the Commission
should reject the proposed electric service tariff sheets GMO filed September 5,
2008 that initiated this general rate increase case.  GMO shall be
authorized to file revised tariff sheets containing rate schedules for electric
service designed to produce an increase in overall Missouri jurisdictional gross
annual base electric revenues, exclusive of any applicable license, occupation,
franchise, gross receipts taxes or other similar fees or taxes, of $48.0 million
for its operations serving the

    
 

     

      
        

      

    

    
 

    territory
it formerly served as Aquila Networks-MPS (“MPS”), and $15.0 million for its
operations serving the territory it formerly served as Aquila Network-L&P
(“L&P”), effective for electric service rendered on and after September 1,
2009, provided however, that the Iatan 1 Air Quality Control System ("AQCS")
facilities meet the Staff's in-service criteria which are attached to the Direct
Testimony of Brent Davis as Schedule BCD-2 in Case No. ER-2009-0089 by May 30,
2009.  The Signatories agree that GMO’s “base energy cost” included in
the new rates and for GMO’s FAC will be $0.02348 for MPS and $0.01642 for
L&P.  Exemplar revised tariff sheets designed to implement this
2009 GMO Stipulation are attached as Schedule 1.  Subject to the
provisions herein, the stipulated rate increase resolves this case.

     

    2.           Rate
Design

     

    The Signatories agree that the rate
design shall be on an equal percentage across the board basis for each rate
class; and within each rate class, all energy, demand and service charges shall
receive the same equal percentage increase as the overall class increase, i.e., each rate element shall
receive the same percentage increase.  The Signatories agree that the
return check charge will increase to $30.

     

    3.           Customer Class Cost of
Service Study

     

    GMO
agrees to file a new class cost of service study case by June 30,
2010.

     

    4.           Vegetation Management and
Infrastructure Inspection

     

    The
Signatories agree that there shall be no tracker for vegetation management or
infrastructure inspection activities, but that GMO shall create sub-accounts for
each where the costs for these activities shall be booked for
GMO.  GMO shall submit quarterly reports detailing GMO’s vegetation
management activities and expenses to the

    
 

     

      
        

      

    

     

     

    Commission’s
Energy Department.  GMO agrees to maintain records to separately
identify the costs to implement the Commission’s new Vegetation Management
regulations using Federal Energy Regulatory Commission accounts 593000
(distribution) and 571005-571006 (transmission); GMO shall use department 752
for MPS and department 952 for L&P.  GMO states that it is in the
process of setting up appropriate accounts to track infrastructure and
reliability reporting costs.

     

    5.           Prudence and In-Service
Timing of Iatan 1

     

    No
Signatory to this 2009 GMO Stipulation shall argue that anyone
is prohibited from arguing or presenting evidence in the next
GMO  general rate case challenging the prudence of any Iatan 1
construction cost or that Iatan 1 should have been operating at full
generation capacity sooner than the actual date that Iatan 1 is found to be
fully operational and used for service; provided, however, that any proposed
disallowance of rate base for imprudence under this paragraph shall be limited
to a maximum amount of GMO rate base no greater than $15 million inclusive of
Iatan common costs.  GMO acknowledges Kansas City Power & Light
Company has represented that Iatan 1 and Iatan common costs will not exceed $733
million on a total project basis.  Should the Commission find that
GMO, respecting any Signatory’s construction audit of these costs, (a) failed to
provide material and relevant information which was in GMO’s control, custody,
or possession, or which should have been available to GMO through reasonable
investigation, (b) misrepresented facts relevant to charges to Iatan 1 or Iatan
common costs, or (c) engaged in the obstruction of lawful discovery, said
Non-Utility Signatory is not bound to proposing a disallowance to GMO’s Missouri
jurisdictional rate base no greater than $15 million inclusive of Iatan common
costs in aggregate amount with

    
 

     3

      
        

      

    

     

     

    regard to
such construction audit.  GMO shall maintain Caseworks for the use of
the Non-Utility Signatories.  The Non-Utility Signatories may continue
their construction audits of Iatan 1 and Iatan 2 prior to GMO filing its Iatan 2
rate case.  GMO will facilitate the resolution of all outstanding
discovery disputes with the Non-Utility Signatories and cooperate with the
Non-Utility Signatories in any construction audits of Iatan 1 and Iatan
2.  GMO shall have the right to object, or to continue to object, to
discovery of the Non-Utility Signatories under applicable law or Commission
rule.  GMO and the Non-Utility Signatories will seek timely resolution
of discovery disputes.

     

    6.           Allocations
of Common Plant for Iatan 1 and 2

     

    (a)           The
Signatories agree that GMO can record to a regulatory asset the depreciation and
carrying costs associated with the Iatan 1 Air Quality Control System (“AQCS”)
and identified Iatan common facilities costs appropriately recorded to Electric
Plant in Service that are not included in rate base in the current rate
case.  Depreciation and carrying costs will continue to be deferred to the
regulatory asset until the date new rates become effective resulting from GMO’s
next general rate case.  Amortization of the accumulated deferred
costs will begin at that time based on the depreciable life of the Iatan 1 AQCS
plant.

     

    (b)           The
determination of the value of the owners of Iatan 1 due from other owners of
Iatan 2 joining as additional owners of common plant already paid for by the
Iatan 1 owners has not been calculated, and is to be accrued as an offset to
common plant costs.

     

    (c)           If
Staff's in-service criteria are met by May 30, 2009, the Signatories agree to
the use of “construction accounting” for the remaining Iatan 1 AQCS and
identified

    
 

     4

      
        

      

    

     

     

    Iatan
common facilities prudent costs incurred after the true-up cutoff of April 30,
2009.  The additional Iatan 1 AQCS and identified Iatan common
facilities prudent costs incurred as of the true-up cutoff of April 30, 2009 and
to be included in rate base in this case will be provided as part of a
late-filed Schedule 4 to this 2009 GMO Stipulation that will be filed in this
case by June 8, 2009.   Additional amounts for the remaining
Iatan 1 AQCS and identified Iatan common facilities prudent costs incurred after
the true-up cutoff of April 30, 2009, based on invoices timely booked or
approved for payment on or before May 31, 2009, will be added to the respective
April 30, 2009 amounts, and provided by GMO in the late-filed Schedule 4 to this
2009 GMO Stipulation that will be filed in this case by June 8,
2009.  “Construction accounting” is defined in the Stipulation and
Agreement authorizing Kansas City Power & Light Company’s Experimental
Regulatory Plan as finally amended and approved by the Commission in Case No.
EO-2005-0329 at page 43, Section III.3.d.vii of that Stipulation and
Agreement.  The Signatories agree the amount of common plant costs to
include in rates in this case shall be calculated by the same method that is
used in the illustrative calculation attached to this 2009 GMO Stipulation as
Schedule 2, based on invoices timely booked or approved for payment on or before
May 31, 2009.  Any deferred depreciation expense and carrying costs
will be offset by accumulated deferred income taxes on the Iatan 1 and common
plant prudent costs not included in rate base in the current rate
case.  The deferred expenses will receive rate base treatment, and
consistent with the Commission treatment of these types of deferrals, the
deferred income taxes will be included in GMO’s rate base for
L&P.  GMO agrees to calculate the amount due from the other Iatan
2 owners and reflect that amount as an offset to the common plant
costs.  The carrying costs will be

    
 

     5

      
        

      

    

     

     

    calculated
using a return on equity component of 10.2%.  GMO’s actual debt cost
will be adjusted to reflect imputed investment-grade debt, as ordered by the
Commission in its Report and
Order in Case No. EM-2007-0374 where it authorized Great Plains Energy’s
acquisition of GMO.

     

    7.           Allowance
for Funds Used During Construction Rate for Iatan 2

     

    The
Allowance for Funds Used During Construction (“AFUDC”) rate authorized in this
2009 GMO Stipulation will utilize a return on equity component of 10.2%;
however, this agreed upon rate does not affect the discounted AFUDC rate
established in the Non-Unanimous Stipulation and Agreement that resolved the
Kansas City Power & Light Company general rate increase case before this
Commission in Case No. ER-2009-0089.

     

    8.           Crossroads

     

    GMO
agrees to explore all reasonable options to add generating capacity to GMO’s
system and use its best efforts to determine the best terms available for each
such option. GMO will provide each Non-Utility Signatory a written report of its
efforts and decisions resulting from these activities by no later than the date
GMO files its next general rate case in Missouri.  In addition, GMO
agrees to provide supporting information to each Non-Utility Signatory that
requests information regarding the written report, subject to the Commission
rule 4 CSR 240-2.135 on the treatment of confidential
information.  Each Signatory reserves the right to assert any position
on the issue of whether the Crossroads Generating Facility located in
Mississippi should be included or excluded from GMO’s rate base and operating
expenses in any future proceeding.

    

    6

      
        

      

    

    
 

    9.           Sibley
and Jeffrey Air Quality
Control System
Equipment 

     

    The
Signatories agree that the Sibley and the Jeffrey Energy Center AQCS equipment
will be allowed into rate base if fully operational and used for service by May
30, 2009.  No Signatory to this 2009 GMO Stipulation shall argue that
anyone is prohibited from arguing or presenting evidence in GMO’s
next general rate case to challenge the prudence of any Sibley or Jeffrey
Energy Center AQCS construction cost.

     

    10.           Economic Relief Pilot
Program

     

    The
Signatories agree that GMO can defer 50% of the costs of its Economic Relief
Pilot Program in a regulatory asset until the next GMO general rate case, with
cost recovery to be determined at that time.  The remaining 50% of
such cost will be borne by GMO’s shareholders.    GMO agrees
to address all concerns raised by Staff in rebuttal testimony, specifically
related to the language regarding discontinuation of customer participation, and
the language regarding reinstatement of former participants, as contained in
Attachment Schedule ADD-1 to the Surrebuttal Testimony of Company witness Allen
Dennis prefiled in this case, Case No. ER-2009-0090.  The Signatories
agree that this program should be implemented, but that it should not be
considered a demand side management program.  The Signatories agree
that the exemplar tariff sheets labeled P.S.C. MO. No. 1, Original Sheets Nos.
62.15, 62.16, 62.17, and 62.18 attached to this 2009 GMO Stipulation as part of
Schedule 1 capture the Signatories’ agreement regarding this
program.

    

    

    7

      
        

      

    

     

    
 

    
      	
               
      

            	
              11.

            	
              Allocation
      of off-system sales and Staff’s methodology for fuel and purchased power
      allocations between MPS and
L&P

            

    

    

    The
methodology set out in attached Schedule 3, which includes Staff’s methodology
described at pages 75-80 of the Staff Report, Cost of Service
filed in Case No. ER-2009-0090 on February 13, 2009 in the section labeled 5. Allocation of Fuel and Purchased
Power Costs, shall be used to allocate off-system sales, fuel expenses
and purchased power expenses between MPS and L&P.

     

    12.           Income
Tax Cost of Removal

     

    GMO
agrees not to pursue in this case the Income Tax Cost of Removal issue it raised
in this case, and that GMO will never raise this Income Tax Cost of Removal
issue again in any future proceeding.

     

    
      	
               
      

            	
              13.

            	
              Maintenance
      Expenses

            

    

    

    The
Signatories agree that GMO is authorized to record costs incremental to typical
maintenance costs related to power plant turbine overhauls in advance of
performing this type of maintenance at the power plants.  This method
is used to match the utilization of the power plant for the generation of
electricity with incremental costs related to power plant turbine overhauls that
are required periodically based on the number of starts for certain gas-fired
power plants.  The accounting for this accrual is to record the
authorized cost of service as expense in the period collected in rates with an
offsetting credit to a regulatory liability until the major maintenance is
performed.  Use of this methodology referenced in this paragraph shall
have no ratemaking effect in any future rate cases.

    

     

    8

      
        

      

    

    
 

    14.           Demand-Side Management
(“DSM”)

     

    (a)           The
Signatories agree that for ratemaking purposes GMO will defer the costs of its
DSM programs in a regulatory asset, and annually calculate AFUDC on the balance
in that regulatory asset.  DSM programs are defined as demand response
and energy efficiency programs.  The prudently-incurred costs included
in the regulatory asset balance will be amortized over a ten- (10) year
period.  When new rates go into effect reflecting amortization
recovery as a result of future general rate proceedings, the prudently-incurred
costs included in the regulatory asset balance will be added to rate base, GMO
will stop accruing AFUDC on the amount included in rate base, and GMO will begin
amortizing the balance.  Additional DSM program costs incurred after
the effective date of a final Report and Order in GMO’s next general electric
rate proceeding following this case, Case No. ER-2009-0090, will be treated in
the same manner, but will be deferred in a different sub-account by
vintage.

     

    (b)           GMO also
agrees in its next Chapter 22 Resource Planning filing to include at least one
alternative resource plan that demonstrates energy reductions from demand side
resources of at least 1% of the projected retail energy requirements per year
over the 20-year planning horizon, assuming a net-to-gross ratio of
1.0.

     

    15.           Supplemental
Weatherization and Minor Home Repair Program

     

    GMO
agrees to present the Supplemental Weatherization and Minor Home Repair Program
to the customer program advisory group (“CPAG”) at the earliest
opportunity.  GMO remains committed to the program, but believes input
from the CPAG would be beneficial to the finalization and implementation of the
program.

    

    9

      
        

      

    

     

    
 

    16.           Low
Income/Weatherization Issues

     

    GMO
agrees to take an active role in the coordination of the exchange of information
between the City of Kansas City, Missouri and the state agencies that administer
the LIHEAP programs to facilitate the referral of customers who might benefit
from GMO’s low-income weatherization program.

     

    17.           Pension
Agreement

     

    GMO and
Staff will file a separate Non-Unanimous Stipulation and Agreement Regarding
Pensions in this proceeding.

     

    18.           Fuel Adjustment
Clause

     

    The
Signatories agree that GMO’s FAC shall be clarified and modified as contained in
the exemplar tariff sheets attached as part of Schedule 1, and as
follows:

     

    
      	
               
      

            	
              a.

            	
              GMO’s
      FAC tariff sheets shall list all the expenses and revenues that flow
      through its FAC;

            

    

    

    
      	
               
      

            	
              b.

            	
              Monthly
      fuel and purchased power expenses will be allocated to MPS and L&P on
      a going forward basis using Staff’s methodology for allocating such
      expenses between MPS and L&P presented in testimony in this case, and
      as addressed in § 11 of this 2009 GMO
  Stipulation;

            

    

    

    
      	
               
      c.  

            	
                
      To aid in FAC tariff, prudence and true-up reviews, GMO shall submit to
      Staff the following:

            

    

    

    
      	
               
      

            	
              •

            	
              As
      part of the information GMO submits when it files a tariff modification to
      change its cost adjustment factor (“CAF”), GMO’s calculation of the
      interest included in the proposed
CAF;

            

    

    

    
      	
               
      

            	
              •

            	
              In
      addition to the monthly reports required by 4 CSR 240-3.161(5), GMO’s
      Southwest Power Pool (“SPP”) Energy Imbalance Service (“EIS”) market
      settlements and revenue neutrality uplift
  charges;

            

    

    

    
      	
               
      

            	
              •

            	
              At
      GMO’s corporate headquarters or at some other mutually agreed upon place
      within a mutually agreed upon time for review, a copy of each and every
      coal and transportation contract GMO has that is in
  effect;

            

    

    

     

    10

    
      
        

      

    
      	
               
      

            	
              •

            	
              Within
      30 days of the effective date of each and every coal and transportation
      contract GMO enters into, both notice to the Staff of the contract and, at
      GMO’s corporate headquarters or at some other mutually agreed upon place,
      the contracts for review;

            

    

    

    
      	
               
      

            	
              •

            	
              At
      GMO’s corporate headquarters or at some other mutually agreed upon place
      within a mutually agreed upon time, a copy for review of each and every
      natural gas contract GMO has that is in
effect;

            

    

    

    
      	
               
      

            	
              •

            	
              Within
      30 days of the effective date of each and every natural gas contract GMO
      enters into, both notice to the Staff of the contract and at GMO’s
      corporate headquarters or at some other mutually agreed upon place a copy
      of the contract for review;

            

    

    

    
      	
               
      

            	
              •

            	
              A
      copy of each and every GMO hedging policy that is in effect for Staff to
      retain;

            

    

    

    
      	
               
      

            	
              •

            	
              Within
      30 days of any change in a GMO hedging policy, a copy of the changed
      hedging policy for Staff to retain;

            

    

    

    
      	
               
      

            	
              •

            	
              A
      copy of GMO’s internal policy for participating in the SPP EIS market,
      including any GMO sales/purchases from that market for Staff to
      retain;

            

    

    

    
      	
               
      

            	
              •

            	
              If
      GMO revises any internal policy for participating in the SPP EIS market,
      within 30 days of that revision, a copy of the revised policy with the
      revisions identified for Staff to retain;
and

            

    

    

    
      	
               
      

            	
              •

            	
              In
      addition to supplying the information required by 4 CSR 240-3.190(3) for
      any accidents occurring at a power plant involving serious physical injury
      or death or property damage in excess of $100,000, the information for
      every incident at a power plant in which GMO has any ownership interest
      that involves serious physical injury or death or property damage in
      excess of $100,000 in the
aggregate.

            

    

    

    Notwithstanding
the provisions of this paragraph, the Non-Utility Signatories reserve the right
to contest in any future proceeding whether GMO’s FAC should include all costs
and revenues associated with all energy and capacity transactions made by GMO,
including purely financial transactions.  Further, the Signatories
reserve the right to assert a position in any future proceedings regarding the
issue of whether GMO’s FAC as

    
 

     

     11

      
        

      

    

    
 

    originally
authorized by the Commission in Case No. ER-2007-0004 has included off-system
sales.

     

    GENERAL
PROVISIONS OF STIPULATION

     

    18.           Any
Signatory may file suggestions, a memorandum or other pleading in support of
this 2009 GMO Stipulation.  Each Signatory shall have the right to
file suggestions, a memorandum or other pleadings in response.  The
contents of any such suggestions, memorandum or other pleading provided by any
Signatory will be its own.

     

    19.           This
2009 GMO Stipulation is being entered into solely for the purpose of disposing
of Case No. ER-2009-0090.  Except as expressly and specifically
addressed otherwise in this 2009 GMO Stipulation, no Signatory to this 2009 GMO
Stipulation shall be deemed to have approved, accepted, agreed, consented, or
acquiesced in, including without limitation, any procedural principle, question
of Commission authority, accounting authority order principle, cost of capital
principle or methodology, capital structure principle or methodology,
decommissioning methodology, ratemaking principle, valuation methodology, cost
of service methodology or determination, depreciation principle or method, rate
design methodology, cost allocation principle or methodology, cost recovery
principle or methodology, or prudence question that may underlie this 2009 GMO
Stipulation, or for which provision is made in this 2009 GMO
Stipulation.

     

    20.           This
2009 GMO Stipulation represents a negotiated settlement.  Except as
specified herein, the Signatories to this 2009 GMO Stipulation shall not be
prejudiced, bound by, or in any way affected by the terms of this 2009 GMO
Stipulation:  (a) in any future proceeding; (b) in any proceeding
currently pending under a separate docket; (c) in

    
 

     12

      
        

      

    

    
 

    any
pending judicial review and/or appeal including, but not limited to, those
arising from Commission Case Nos. ER-2007-0004, EO-2008-0216, EO-2008-0415,
EO-2009-0254 and EM-2007-0374; and/or (d) in this proceeding should the
Commission decide not to approve this 2009 GMO Stipulation, or in any way
condition its approval of same.

     

    21.           The
provisions of this 2009 GMO Stipulation have resulted from extensive
negotiations between the Signatories and are interdependent.  If the
Commission does not approve and adopt the terms of this 2009 GMO Stipulation in
total, it shall be void and none of the Signatories shall be bound, prejudiced,
or in any way affected by any of the agreements or provisions hereof, unless
otherwise agreed to by the Signatory.

     

    22.           If
approved and adopted by the Commission, this 2009 GMO Stipulation shall
constitute a binding agreement among the Signatories.  The Signatories
shall cooperate in defending the validity and enforceability of this 2009 GMO
Stipulation and the operation of this 2009 GMO Stipulation according to its
terms.

     

    23.           This
2009 GMO Stipulation does not constitute a contract with the
Commission.  Acceptance of this 2009 GMO Stipulation by the Commission
shall not be deemed as constituting an agreement on the part of the Commission
to forego the use of any discovery, investigative or other power which the
Commission presently has.  Thus, nothing in this 2009 GMO Stipulation
is intended to impinge or restrict in any manner the exercise by the Commission
of any statutory right, including the right to access information, or any
statutory obligation.

     

    24.           If
the Commission does not unconditionally approve this 2009 GMO Stipulation
without modification, and notwithstanding its provision that it shall become
void thereon, neither this 2009 GMO Stipulation, nor any matters associated with
its 

    
 

     13

      
        

      

    

     

     

    consideration
by the Commission, shall be considered or argued to be a waiver of the rights
that any Signatory has to a hearing on the issues presented by this 2009 GMO
Stipulation, for cross-examination, or for a decision in accordance with Section
536.080 RSMo 2000 or Article V, Section 18 of the Missouri Constitution, and
each Signatory shall retain all procedural and due process rights as fully as
though this 2009 GMO Stipulation had not been presented for approval, and any
suggestions, memoranda, testimony or exhibits that have been offered or received
in support of this 2009 GMO Stipulation shall thereupon become privileged as
reflecting the substantive content of settlement discussions and shall be
stricken from and not be considered as part of the administrative or evidentiary
record before the Commission for any further purpose whatsoever, unless
otherwise agreed to by all of the Signatories.

     

    25.           If
the Commission accepts the specific terms of this 2009 GMO Stipulation, the
Signatories waive their respective rights to cross-examine witnesses; their
respective rights to present oral argument and written briefs pursuant to
Section 536.080.1 RSMo 2000; and their respective rights to judicial review
pursuant to Section 386.510 RSMo 2000.  The Signatories agree that the
pre-filed testimony and exhibits of the Signatories shall be entered into the
record without the necessity of the witnesses taking the witness
stand.

     

    26.           If
the Commission has questions for representatives or witnesses of one or more of
the Signatories, the Signatories shall make available, at any on-the-record
session, their witnesses and attorneys for the issues settled by this 2009 GMO
Stipulation, provided that all of the Signatories are given adequate notice of
the on-the-record session.  The
Signatories agree to cooperate in presenting this 2009 GMO Stipulation to the

     

     

    14

    
      
        

      

    

     

     

     

    Commission
for approval, and shall take no action, directly or indirectly, in opposition to
approval of this 2009 GMO Stipulation.

     

    27.           With
the exception of the separate Non-Unanimous Stipulation and Agreement Regarding
Pensions contemplated in this 2009 GMO Stipulation to be filed by the Staff and
GMO, this 2009 GMO Stipulation embodies the entirety of the agreements between
the Signatories in this case and may be modified by the Signatories only by a
written amendment executed by all of the Signatories.

     

    WHEREFORE, for the foregoing
reasons, the Signatories respectfully request that the Commission issue an Order
approving the terms and conditions of this Non-Unanimous Stipulation and
Agreement.

     

    Respectfully
submitted,

     

    

     

    
      	
              STAFF
      OF THE MISSOURI PUBLIC SERVICE COMMISSION

              /s/
      Nathan Williams by JMF

              _________________________________

              Kevin
      A. Thompson, MBE #36288

              General
      Counsel

              Steven
      Dottheim, MBE #29149

              Chief
      Deputy General Counsel

              Nathan
      Williams, MBE #35512

              Deputy
      General Counsel

              Missouri
      Public Service Commission

              P.O.
      Box 360

              Jefferson
      City, MO  65102

              (573)
      751-8702 (Voice - Williams)

              (573)
      751-7489 (Voice - Dottheim)

              (573)
      751-2690 (Voice - Thompson)

              (573)
      751-9285 (Fax)

              nathan.williams@psc.mo.gov

              steve.dottheim@psc.mo.gov

              kevin.thompson@psc.mo.gov

               

               

               

               

               

            	
              KCP&L
      GREATER MISSOURI OPERATIONS COMPANY

              /s/
      James M. Fischer

              ________________________________

              William
      G. Riggins, MBE #42501

              General
      Counsel

              Curtis
      Blanc, MBN#58052

              Managing
      Attorney - Regulatory

              Kansas
      City Power & Light Company

              (816)
      556-2785

              (816)
      556-2787 (Fax)

              bill.riggins@kcpl.com

              curtis.blanc@kcpl.com

               

              James
      M. Fischer, MBE #27543

              Fischer
      & Dority, P.C.

              101
      Madison Street, Suite 400

              Jefferson
      City, MO  65101

              (573)
      636-6758

              (573)
      636-0383 (Fax)

              jfischerpc@aol.com

               

               

              15

               

               

               

               

               

               

              Karl
      Zobrist, MBN #28325

              Roger
      W. Steiner, MBN #39586

              Sonnenschein
      Nath & Rosenthal LLP

              4520
      Main Street, Suite 1100

              Kansas
      City, MO  64111

              (816)
      460-2545

              (816)
      531-7545 (Fax)

              kzobrist@sonnenschein.com

              rsteiner@sonnenschein.com

               

            
	
              OFFICE
      OF THE PUBLIC COUNSEL

               

               

               

              /s/
      Lewis R. Mills, Jr. by JMF

              _______________________________

              Lewis
      R. Mills, Jr., MBE #35275

              Public
      Counsel

              P.O.
      Box 2230

              Jefferson
      City,  MO  65102

              (573)
      751-1304

              (573)
      751-5562 (Fax)

              lewis.mills@ded.mo.gov

               

            	
              MISSOURI
      DEPARTMENT OF NATURAL RESOURCES

               

               

              /s/
      Harry Bozian by JMF

              ________________________________

              Harry
      Bozoian, MBE # 37535

              Deputy
      General Counsel

              P.O.
      Box 176

              Jefferson
      City, MO  65102

              (573)
      751-0323

              (573)
      526-3444 (Fax)

              harry.bozoian@dnr.mo.gov

               

            
	
              FEDERAL
      EXECUTIVE AGENCIES

               

               

               

               

              _____________________________________

              Shayla
      L. McNeill

              Federal
      Executive Agencies

              139
      Barnes Ave, Suite 1

              Tyndall
      AFB, FL 32403

            	
              AG
      PROCESSING, INC., WAL-MART STORES, INC. AND SEDALIA INDUSTRIAL ENERGY
      USERS

               

               

              ________________________________

              Stuart
      W. Conrad MBE #23966

              David
      L. Woodsmall MBE #40747

              3100
      Broadway, Suite 1209

              Kansas
      City, Missouri 64111

              (816)
      753-1122

              (816)756-0373
      (Fax)

              stucon@fcplaw.com

               

            
	
              UNION
      ELECTRIC CO., d/b/a AMERENUE

               

               

               

               

              __________________________________

              James
      B. Lowery, MBE #40503

              Smith
      Lewis, LLP

              111
      South Ninth St., Suite 200

              P.O.
      Box 918

              Columbia
      MO 65205-0918

              (573)
      443-3141

              (573)
      442-6686 (Fax)

              lowery@smithlewis.com

               

            	
              HOSPITAL
      INTERVENORS

               

               

               

               

              ___________________________________

              James
      P. Zakoura

              Smithyman
      & Zakoura, Chartered

              750
      Commerce Plaza II

              7400
      W. 110th
      Street

              Overland
      Park KS 66210-2346

              (913)
      661-9800

              (913)
      661-9863 (Fax)

              zakoura@smizak-law.com

               

               

              16

            

    

    

    DOGWOOD
ENERGY, LLC

    

    

    /s/ Carl
J. Lumley

    __________________________________

    Carl J.
Lumley, #32869

    130 S.
Bemiston, Suite 200

    Clayton,
Missouri 63105

    (314)
725-8788

    (314)
725-8789 (Fax)

    clumley@lawfirmemail.com

    

    

    

    CERTIFICATE OF
SERVICE

    

    I do
hereby certify that a true and correct copy of the foregoing document has been
hand delivered, emailed or mailed, postage prepaid, this 22nd day of May, 2009,
to all counsel of record.

     

    /s/ James M.
Fischer

    James M.
Fischer

    
17SECURITIES
PURCHASE AGREEMENT

     

    SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of May
15, 2009, by and among Wellstar International Inc., a Nevada corporation, with
headquarters located at 6911 Pilliod Road, Holland, OH 43528  (the “Company”), and each of the
purchasers set forth on the signature pages hereto (the “Buyers”).

     

    WHEREAS:

     

    A.           The
Company and the Buyers are executing and delivering this Agreement in reliance
upon the exemption from securities registration afforded by the rules and
regulations as promulgated by the United States Securities and Exchange
Commission (the “SEC”)
under the Securities Act of 1933, as amended (the “1933 Act”);

     

    B.           Buyers
desire to purchase and the Company desires to issue and sell, upon the terms and
conditions set forth in this Agreement  13% secured convertible notes of
the Company, in the form attached hereto as Exhibit “A”, in the aggregate
principal amount of Seventy-Nine Thousand Five Hundred Dollars ($79,500)
(together with any note(s) issued in replacement thereof or as a dividend
thereon or otherwise with respect thereto in accordance with the terms thereof,
the “Notes”),
convertible into shares of common stock, par value $.001 per share, of the
Company (the “Common
Stock”), upon the terms and subject to the limitations and conditions set
forth in such Notes.

     

    C.           Each
Buyer wishes to purchase, upon the terms and conditions stated in this
Agreement, such principal amount of Notes as is set forth immediately below its
name on the signature pages hereto; and

     

    D.           Contemporaneous
with the execution and delivery of this Agreement, the parties hereto are
executing and delivering a Registration Rights Agreement, in the form attached
hereto as Exhibit “C”
(the “Registration Rights
Agreement”), pursuant to which the Company has agreed to provide certain
registration rights under the 1933 Act and the rules and regulations promulgated
thereunder, and applicable state securities laws.

     

    NOW THEREFORE, the Company and
each of the Buyers severally (and not jointly) hereby agree as
follows:

     

    1.           PURCHASE
AND SALE OF NOTES.

     

    a.           Purchase
of Notes.  On the Closing Date (as defined below), the Company
shall issue and sell to each Buyer and each Buyer severally agrees to purchase
from the Company such principal amount of Notes as is set forth immediately
below such Buyer’s name on the signature pages hereto, which, together with any
subsequent closings provided for in Section 1(d) below, may equal an aggregate
of up to Seventy-Nine Thousand Five Hundred Dollars ($79,500) principal amount
of Notes.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    b.           Form of
Payment.  On the Closing Date (as defined
below),  each Buyer shall pay the purchase price for the Notes to be
issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire
transfer of immediately available funds to the Company, in accordance with the
Company’s written wiring instructions, against delivery of the Notes in the
principal amount equal to the Purchase Price as is set forth immediately below
such Buyer’s name on the signature pages hereto, and  the Company
shall deliver such Notes duly executed on behalf of the Company, to such Buyer,
against delivery of such Purchase Price.

     

    c.           Closing
Date.  Subject to the satisfaction (or written waiver) of the
conditions thereto set forth in Section 6 and Section 7 below, the date and time
of the issuance and sale of the Notes pursuant to this Agreement (the “Closing Date”) shall be 12:00
noon, Eastern Standard Time on May 15, 2009, or such other mutually agreed upon
time.  The closing of the transactions contemplated by this Agreement
(the “Closing”) shall
occur on the Closing Date at such location as may be agreed to by the
parties.

     

    2.           BUYERS’
REPRESENTATIONS AND WARRANTIES.  Each Buyer severally (and not
jointly) represents and warrants to the Company solely as to such Buyer
that:

     

    a.           Investment
Purpose.  As of the date hereof, the Buyer is purchasing the
Notes and the shares of Common Stock issuable upon conversion of or otherwise
pursuant to the Notes (including, without limitation, such additional shares of
Common Stock, if any, as are issuable  on account of interest on the
Notes,  as a result of the events described in Sections 1.3 and 1.4(g)
of the Notes and Section 2(c) of the Registration Rights Agreement
or  in payment of the Standard Liquidated Damages Amount (as defined
in Section 2(f) below) pursuant to this Agreement, such shares of Common Stock
being collectively referred to herein as the “Conversion Shares”) and the
shares of Common Stock issuable upon exercise thereof (the “Warrant Shares” and,
collectively with the Notes and Conversion Shares, the “Securities”) for its own
account and not with a present view towards the public sale or distribution
thereof, except pursuant to sales registered or exempted from registration under
the 1933 Act; provided, however, that by
making the representations herein, the Buyer does not agree to hold any of the
Securities for any minimum or other specific term and reserves the right to
dispose of the Securities at any time in accordance with or pursuant to a
registration statement or an exemption under the 1933 Act.

     

    b.           Accredited
Investor Status.  The Buyer is an “accredited investor” as that
term is defined in Rule 501(a) of Regulation D (an “Accredited
Investor”).

     

    c.           Reliance
on Exemptions.  The Buyer understands that the Securities are
being offered and sold to it in reliance upon specific exemptions from the
registration requirements of United States federal and state securities laws and
that the Company is relying upon the truth and accuracy of, and the Buyer’s
compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Buyer set forth herein in order to determine the
availability of such exemptions and the eligibility of the Buyer to acquire the
Securities.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    d.           Information.  The
Buyer and its advisors, if any, have been, and for so long as the Notes remain
outstanding will continue to be, furnished with all materials relating to the
business, finances and operations of the Company and materials relating to the
offer and sale of the Securities which have been requested by the Buyer or its
advisors.  The Buyer and its advisors, if any, have been, and for so
long as the Notes remain outstanding will continue to be, afforded the
opportunity to ask questions of the Company.  Notwithstanding the
foregoing, the Company has not disclosed to the Buyer any material nonpublic
information and will not disclose such information unless such information is
disclosed to the public prior to or promptly following such disclosure to the
Buyer.  Neither such inquiries nor any other due diligence
investigation conducted by Buyer or any of its advisors or representatives shall
modify, amend or affect Buyer’s right to rely on the Company’s representations
and warranties contained in Section 3 below.  The Buyer understands
that its investment in the Securities involves a significant degree of
risk.  The Buyers are not aware of any facts that may constitute a
breach of any of the Company’s representations and warranties made
herein.

     

    e.           Governmental
Review.  The Buyer understands that no United States federal or
state agency or any other government or governmental agency has passed upon or
made any recommendation or endorsement of the Securities.

     

    f.           Transfer
or Re-sale.  The Buyer understands that  except as
provided in the Registration Rights Agreement, the sale or re-sale of the
Securities has not been and is not being registered under the 1933 Act or any
applicable state securities laws, and the Securities may not be transferred
unless  the Securities are sold pursuant to an effective registration
statement under the 1933 Act,  the Company shall have received an
opinion of counsel reasonably acceptable to the Company and its counsel that
shall be in form, substance and scope customary for opinions of counsel in
comparable transactions to the effect that the Securities to be sold or
transferred may be sold or transferred pursuant to an exemption from such
registration, which opinion shall be accepted by the Company,  the
Securities are sold or transferred to an “affiliate” (as defined in Rule 144
promulgated under the 1933 Act (or a successor rule) (“Rule 144”)) of the Buyer who
agrees to sell or otherwise transfer the Securities only in accordance with this
Section 2(f) and who is an Accredited Investor,  the Securities are
sold pursuant to Rule 144, or  the Securities are sold pursuant to
Regulation S under the 1933 Act (or a successor rule) (“Regulation S”), and the
Company shall have received an opinion of counsel reasonably acceptable to the
Company and its counsel that shall be in form, substance and scope customary for
opinions of counsel in corporate transactions, which opinion shall be accepted
by the Company; (ii) any sale of such Securities made in reliance on Rule 144
may be made only in accordance with the terms of said Rule and further, if said
Rule is not applicable, any re-sale of such Securities under circumstances in
which the seller (or the person through whom the sale is made) may be deemed to
be an underwriter (as that term is defined in the 1933 Act) may require
compliance with some other exemption under the 1933 Act or the rules and
regulations of the SEC thereunder; and (iii) neither the Company nor any other
person is under any obligation to register such Securities under the 1933 Act or
any state securities laws or to comply with the terms and conditions of any
exemption thereunder (in each case, other than pursuant to the Registration
Rights Agreement).  Notwithstanding the foregoing or anything else
contained herein to the contrary, the Securities may be pledged as collateral in
connection with a bona fide margin account
or other lending arrangement.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    g.           Legends.  The
Buyer understands that the Notes and, until such time as the Conversion Shares
have been registered under the 1933 Act as contemplated by the Registration
Rights Agreement or otherwise may be sold pursuant to Rule 144 or Regulation S
without any restriction as to the number of securities as of a particular date
that can then be immediately sold, the Conversion Shares may bear a restrictive
legend in substantially the following form (and a stop-transfer order may be
placed against transfer of the certificates for such Securities):

     

    “The
securities represented by this certificate have not been registered under the
Securities Act of 1933, as amended.  The securities may not be sold, transferred
or assigned in the absence of an effective registration statement for the
securities under said Act, or an opinion of counsel, in form, substance and
scope customary for opinions of counsel in comparable transactions, that
registration is not required under said Act or unless sold pursuant to Rule 144
or Regulation S under said Act.”

     

    The
legend set forth above shall be removed and the Company shall issue a
certificate without such legend to the holder of any Security upon which it is
stamped, if, unless otherwise required by applicable state securities laws, (a)
such Security is registered for sale under an effective registration statement
filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or
Regulation S without any restriction as to the number of securities as of a
particular date that can then be immediately sold, or (b) such holder provides
the Company with an opinion of counsel, in form, substance and scope customary
for opinions of counsel in comparable transactions, which opinion shall be
reasonably acceptable to the Company’s counsel, to the effect that a public sale
or transfer of such Security may be made without registration under the 1933
Act, which opinion shall be accepted by the Company so that the sale or transfer
is effected or (c) such holder provides the Company with reasonable assurances
that such Security can be sold pursuant to Rule 144 or Regulation S.  The Buyer
agrees to sell all Securities, including those represented by a certificate(s)
from which the legend has been removed, in compliance with applicable prospectus
delivery requirements, if any.

     

    h.           Authorization;
Enforcement. This Agreement and the Registration Rights Agreement have
been duly and validly authorized.  This Agreement has been duly
executed and delivered on behalf of the Buyer, and this Agreement constitutes,
and upon execution and delivery by the Buyer of the Registration Rights
Agreement, such agreement will constitute, valid and binding agreements of the
Buyer enforceable in accordance with their terms.

     

    i.           Residency.  The
Buyer is a resident of the jurisdiction set forth immediately below such Buyer’s
name on the signature pages hereto.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    3.           REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.  The Company represents and
warrants to each Buyer that:

     

    a.           Organization
and Qualification.  The Company and each of its Subsidiaries (as defined
below), if any, is a corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction in which it is incorporated, with
full power and authority (corporate and other) to own, lease, use and operate
its properties and to carry on its business as and where now owned, leased,
used, operated and conducted.  Schedule 3(a) sets forth a
list of all of the Subsidiaries of the Company and the jurisdiction in which
each is incorporated.  The Company and each of its Subsidiaries is duly
qualified as a foreign corporation to do business and is in good standing in
every jurisdiction in which its ownership or use of property or the nature of
the business conducted by it makes such qualification necessary except where the
failure to be so qualified or in good standing would not have a Material Adverse
Effect.  “Material Adverse
Effect” means any of (i) a material and adverse effect on the legality,
validity or enforceability of any document executed in connection with this
financing, (ii) a material and adverse effect on the results of operations,
assets, prospects, business or condition (financial or otherwise) of the Company
and the Subsidiaries, taken as a whole, or (iii) an adverse impairment to the
Company’s ability to perform under any of the documents executed in connection
with this financing.  “Subsidiaries” means any
corporation or other organization, whether incorporated or unincorporated, in
which the Company owns, directly or indirectly, any equity or other ownership
interest.

     

    b.           Authorization;
Enforcement.  (i) The Company has all requisite corporate power
and authority to enter into and perform this Agreement, the Registration Rights
Agreement, the Notes and to consummate the transactions contemplated hereby and
thereby and to issue the Securities, in accordance with the terms hereof and
thereof, (ii) the execution and delivery of this Agreement, the Registration
Rights Agreement, the Notes by the Company and the consummation by it of the
transactions contemplated hereby and thereby (including without limitation, the
issuance of the Notes and the issuance and reservation for issuance of the
Conversion Shares issuable upon conversion or exercise thereof) have been duly
authorized by the Company’s Board of Directors and no further consent or
authorization of the Company, its Board of Directors, or its shareholders is
required, (iii) this Agreement has been duly executed and delivered by the
Company by its authorized representative, and such authorized representative is
the true and official representative with authority to sign this Agreement and
the other documents executed in connection herewith and bind the Company
accordingly, and (iv) this Agreement constitutes, and upon execution and
delivery by the Company of the Registration Rights Agreement, the Notes, each of
such instruments will constitute, a legal, valid and binding obligation of the
Company enforceable against the Company in accordance with its
terms.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    c.           Capitalization.  As
of the date hereof, the authorized capital stock of the Company consists
of  [                           
] shares of Common Stock, of
which[                
] shares are issued and outstanding,
[                ]
shares are reserved for issuance pursuant to the Company’s stock option plans,
[                    ]
shares are reserved for issuance pursuant to securities (other than the Notes)
exercisable for, or convertible into or exchangeable for shares of Common Stock
[                 ]
shares are reserved for issuance upon conversion of the Notes (subject to
adjustment pursuant to the Company’s covenant set forth in Section 4(h)
below).  All of such outstanding shares of capital stock are, or upon
issuance will be, duly authorized, validly issued, fully paid and
nonassessable.  No shares of capital stock of the Company are subject
to preemptive rights or any other similar rights of the shareholders of the
Company or any liens or encumbrances imposed through the actions or failure to
act of the Company.  Except as disclosed in Schedule 3(c), as of the
effective date of this Agreement, (i) there are no outstanding options,
warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal,
agreements, understandings, claims or other commitments or rights of any
character whatsoever relating to, or securities or rights convertible into or
exchangeable for any shares of capital stock of the Company or any of its
Subsidiaries, or arrangements by which the Company or any of its Subsidiaries is
or may become bound to issue additional shares of capital stock of the Company
or any of its Subsidiaries, (ii) there are no agreements or arrangements under
which the Company or any of its Subsidiaries is obligated to register the sale
of any of its or their securities under the 1933 Act (except the Registration
Rights Agreement) and (iii) there are no anti-dilution or price adjustment
provisions contained in any security issued by the Company (or in any agreement
providing rights to security holders) that will be triggered by the issuance of
the Notes, the Conversion Shares.  The Company has furnished to the
Buyer true and correct copies of the Company’s Articles of Incorporation as in
effect on the date hereof (“Articles of Incorporation”),
the Company’s By-laws, as in effect on the date hereof (the “By-laws”), and the terms of
all securities convertible into or exercisable for Common Stock of the Company
and the material rights of the holders thereof in respect
thereto.  The Company shall provide the Buyer with a written update of
this representation signed by the Company’s Chief Executive or Chief Financial
Officer on behalf of the Company as of the Closing Date.

     

    d.           Issuance
of Shares.  The Conversion Shares are duly authorized and
reserved for issuance and, upon conversion of the Notes in accordance with their
respective terms, will be validly issued, fully paid and non-assessable, and
free from all taxes, liens, claims and encumbrances with respect to the issue
thereof and shall not be subject to preemptive rights or other similar rights of
shareholders of the Company and will not impose personal liability upon the
holder thereof.

     

    e.           Acknowledgment
of Dilution.  The Company understands and acknowledges the
potentially dilutive effect to the Common Stock upon the issuance of the
Conversion Shares upon conversion of the Note.  The Company further
acknowledges that its obligation to issue Conversion Shares upon conversion of
the Notes in accordance with this Agreement, the Notes are absolute and
unconditional regardless of the dilutive effect that such issuance may have on
the ownership interests of other shareholders of the Company.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    f.           No
Conflicts.  The execution, delivery and performance of this
Agreement, the Registration Rights Agreement and the Notes by the Company and
the consummation by the Company of the transactions contemplated hereby and
thereby (including, without limitation, the issuance and reservation for
issuance of the Conversion Shares) will not (i) conflict with or result in a
violation of any provision of the Certificate of Incorporation or By-laws or
(ii) violate or conflict with, or result in a breach of any provision of, or
constitute a default (or an event which with notice or lapse of time or both
could become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture, patent,
patent license or instrument to which the Company or any of its Subsidiaries is
a party, or (iii)  to the Company’s knowledge, result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and
state securities laws and regulations and regulations of any self-regulatory
organizations to which the Company or its securities are subject) applicable to
the Company or any of its Subsidiaries or by which any property or asset of the
Company or any of its Subsidiaries is bound or affected (except for such
conflicts, defaults, terminations, amendments, accelerations, cancellations and
violations as would not, individually or in the aggregate, have a Material
Adverse Effect).  Neither the Company nor any of its Subsidiaries is
in violation of its Certificate of Incorporation, By-laws or other
organizational documents and neither the Company nor any of its Subsidiaries is
in default (and no event has occurred which with notice or lapse of time or both
could put the Company or any of its Subsidiaries in default) under, and neither
the Company nor any of its Subsidiaries has taken any action or failed to take
any action that would give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which
the Company or any of its Subsidiaries is a party or by which any property or
assets of the Company or any of its Subsidiaries is bound or affected, except
for possible defaults as would not, individually or in the aggregate, have a
Material Adverse Effect. The businesses of the Company and its Subsidiaries, if
any, are not being conducted, and shall not be conducted so long as a Buyer owns
any of the Securities, in violation of any law, ordinance or regulation of any
governmental entity.  Except as specifically contemplated by this
Agreement and as required under the 1933 Act and any applicable state securities
laws, the Company is not required to obtain any consent, authorization or order
of, or make any filing or registration with, any court, governmental agency,
regulatory agency, self regulatory organization or stock market or any third
party in order for it to execute, deliver or perform any of its obligations
under this Agreement, the Registration Rights Agreement, the Notes in accordance
with the terms hereof or thereof or to issue and sell the Notes in accordance
with the terms hereof and to issue the Conversion Shares upon conversion of the
Notes.  Except as disclosed in Schedule 3(f), all consents,
authorizations, orders, filings and registrations which the Company is required
to obtain pursuant to the preceding sentence have been obtained or effected on
or prior to the date hereof.  The Company is not in violation of the
quotation requirements of the pink sheets (the “Pink Sheets”) and does not
reasonably anticipate that the Common Stock will be removed by the Pink Sheets
in the foreseeable future.  The Company and its Subsidiaries are
unaware of any facts or circumstances which might give rise to any of the
foregoing.

     

    g.           Financial
Statements.  As of their respective dates, the financial
statements of the Company complied as to form in all material respects with
applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto.  Such financial statements have been
prepared in accordance with United States generally accepted accounting
principles, consistently applied, during the periods involved (except (i) as may
be otherwise indicated in such financial statements or the notes thereto, or
(ii) in the case of unaudited interim statements, to the extent they may not
include footnotes or may be condensed or summary statements) and fairly present
in all material respects the consolidated financial position of the Company and
its consolidated Subsidiaries as of the dates thereof and the consolidated
results of their operations and cash flows for the periods then ended (subject,
in the case of unaudited statements, to normal year-end audit
adjustments).  Except as set forth in the financial statements of the
Company the Company has no liabilities, contingent or otherwise, other than (i)
liabilities incurred in the ordinary course of business subsequent to July 31,
2007 and (ii) obligations under contracts and commitments incurred in the
ordinary course of business and not required under generally accepted accounting
principles to be reflected in such financial statements, which, individually or
in the aggregate, are not material to the financial condition or operating
results of the Company.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    h.           Absence
of Certain Changes.  Since July 31, 2007, there has been no
material adverse change and no material adverse development in the assets,
liabilities, business, properties, operations, financial condition, results of
operations or prospects of the Company or any of its Subsidiaries.

     

    i.           Absence
of Litigation.  There is no action, suit, claim, proceeding,
inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the
Company or any of its Subsidiaries, threatened against or affecting the Company
or any of its Subsidiaries, or their officers or directors in their capacity as
such, that could have a Material Adverse Effect.  Schedule 3(i) contains a
complete list and summary description of any pending or, to the knowledge of the
Company, threatened proceeding against or affecting the Company or any of its
Subsidiaries, without regard to whether it would have a Material Adverse
Effect.  The Company and its Subsidiaries are unaware of any facts or
circumstances which might give rise to any of the foregoing.

     

    j.           Patents,
Copyrights, etc.

     

    (i)           The
Company and each of its Subsidiaries owns or possesses the requisite licenses or
rights to use all patents, patent applications, patent rights, inventions,
know-how, trade secrets, trademarks, trademark applications, service marks,
service names, trade names and copyrights (“Intellectual Property”)
necessary to enable it to conduct its business as now operated (and, except as
set forth in Schedule
3(j) hereof, to the best of the Company’s knowledge, as presently
contemplated to be operated in the future); there is no claim or action by any
person pertaining to, or proceeding pending, or to the Company’s knowledge
threatened, which challenges the right of the Company or of a Subsidiary with
respect to any Intellectual Property necessary to enable it to conduct its
business as now operated (and, except as set forth in Schedule 3(j) hereof, to the
best of the Company’s knowledge, as presently contemplated to be operated in the
future); to the best of the Company’s knowledge, the Company’s or its
Subsidiaries’ current and intended products, services and processes do not
infringe on any Intellectual Property or other rights held by any person; and
the Company is unaware of any facts or circumstances which might give rise to
any of the foregoing.  The Company and each of its Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and
value of their Intellectual Property.

     

    k.           No
Materially Adverse Contracts, Etc.  Neither the Company nor any
of its Subsidiaries is subject to any charter, corporate or other legal
restriction, or any judgment, decree, order, rule or regulation which in the
judgment of the Company’s officers has or is expected in the future to have a
Material Adverse Effect.  Neither the Company nor any of its
Subsidiaries is a party to any contract or agreement which in the judgment of
the Company’s officers has or is expected to have a Material Adverse
Effect.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    l.           Tax
Status.  Except as set forth on Schedule 3(l), the Company and
each of its Subsidiaries has made or filed all federal, state and foreign income
and all other tax returns, reports and declarations required by any jurisdiction
to which it is subject (unless and only to the extent that the Company and each
of its Subsidiaries has set aside on its books provisions reasonably adequate
for the payment of all unpaid and unreported taxes) and has paid all taxes and
other governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations, except those
being contested in good faith and has set aside on its books provisions
reasonably adequate for the payment of all taxes for periods subsequent to the
periods to which such returns, reports or declarations apply.  There
are no unpaid taxes in any material amount claimed to be due by the taxing
authority of any jurisdiction, and the officers of the Company know of no basis
for any such claim.  The Company has not executed a waiver with
respect to the statute of limitations relating to the assessment or collection
of any foreign, federal, state or local tax.  Except as set forth on
Schedule 3(l), none of
the Company’s tax returns is presently being audited by any taxing
authority.

     

    m.           Certain
Transactions.  Except as set forth on Schedule 3(m) and except for
arm’s length transactions pursuant to which the Company or any of its
Subsidiaries makes payments in the ordinary course of business upon terms no
less favorable than the Company or any of its Subsidiaries could obtain from
third parties and other than the grant of stock options disclosed on Schedule 3(c), none of the
officers, directors, or employees of the Company is presently a party to any
transaction with the Company or any of its Subsidiaries (other than for services
as employees, officers and directors), including any contract, agreement or
other arrangement providing for the furnishing of services to or by, providing
for rental of real or personal property to or from, or otherwise requiring
payments to or from any officer, director or such employee or, to the knowledge
of the Company, any corporation, partnership, trust or other entity in which any
officer, director, or any such employee has a substantial interest or is an
officer, director, trustee or partner.

     

    n.           Disclosure.  All
information relating to or concerning the Company or any of its Subsidiaries set
forth in this Agreement and provided to the Buyers pursuant to Section 2(d)
hereof and otherwise in connection with the transactions contemplated hereby is
true and correct in all material respects and the Company has not omitted to
state any material fact necessary in order to make the statements made herein or
therein, in light of the circumstances under which they were made, not
misleading.  No event or circumstance has occurred or exists with
respect to the Company or any of its Subsidiaries or its or their business,
properties, prospects, operations or financial conditions, which, under
applicable law, rule or regulation, requires public disclosure or announcement
by the Company but which has not been so publicly announced or disclosed
(assuming for this purpose that the Company’s reports filed under the 1934 Act
are being incorporated into an effective registration statement filed by the
Company under the 1933 Act).

     

    o.           Acknowledgment
Regarding Buyers’ Purchase of Securities.  The Company
acknowledges and agrees that the Buyers are acting solely in the capacity of
arm’s length purchasers with respect to this Agreement and the transactions
contemplated hereby.  The Company further acknowledges that no Buyer
is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to this Agreement and the transactions contemplated
hereby and any statement made by any Buyer or any of their respective
representatives or agents in connection with this Agreement and the transactions
contemplated hereby is not advice or a recommendation and is merely incidental
to the Buyers’ purchase of the Securities.  The Company further
represents to each Buyer that the Company’s decision to enter into this
Agreement has been based solely on the independent evaluation of the Company and
its representatives.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    p.           No
Integrated Offering.  Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales in any security or solicited any offers to
buy any security under circumstances that would require registration under the
1933 Act of the issuance of the Securities to the Buyers.  The
issuance of the Securities to the Buyers will not be integrated with any other
issuance of the Company’s securities (past, current or future) for purposes of
any shareholder approval provisions applicable to the Company or its
securities.

     

    q.           No
Brokers.  Except as set forth in Schedule 3(q), the Company has
taken no action which would give rise to any claim by any person for brokerage
commissions, transaction fees or similar payments relating to this Agreement or
the transactions contemplated hereby.

     

    r.           Permits;
Compliance.  The Company and each of its Subsidiaries is in
possession of all franchises, grants, authorizations, licenses, permits,
easements, variances, exemptions, consents, certificates, approvals and orders
necessary to own, lease and operate its properties and to carry on its business
as it is now being conducted (collectively, the “Company Permits”), and there
is no action pending or, to the knowledge of the Company, threatened regarding
suspension or cancellation of any of the Company Permits.  Neither the
Company nor any of its Subsidiaries is in conflict with, or in default or
violation of, any of the Company Permits, except for any such conflicts,
defaults or violations which, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect.  Since July
31, 2007, neither the Company nor any of its Subsidiaries has received any
notification with respect to possible conflicts, defaults or violations of
applicable laws, except for notices relating to possible conflicts, defaults or
violations, which conflicts, defaults or violations would not have a Material
Adverse Effect.

     

    s.           Environmental
Matters.

     

    (i)           Except
as set forth in Schedule
3(s), there are, to the best of the Company’s knowledge, with respect to
the Company or any of its Subsidiaries or any predecessor of the Company, no
past or present violations of Environmental Laws (as defined below), releases of
any material into the environment, actions, activities, circumstances,
conditions, events, incidents, or contractual obligations which may give rise to
any common law environmental liability or any liability under the Comprehensive
Environmental Response, Compensation and Liability Act of 1980 or similar
federal, state, local or foreign laws and neither the Company nor any of its
Subsidiaries has received any notice with respect to any of the foregoing, nor
is any action pending or, to the Company’s knowledge, threatened in connection
with any of the foregoing.  The term “Environmental Laws” means all
federal, state, local or foreign laws relating to pollution or protection of
human health or the environment (including, without limitation, ambient air,
surface water, groundwater, land surface or subsurface strata), including,
without limitation, laws relating to emissions, discharges, releases or
threatened releases of chemicals, pollutants contaminants, or toxic or hazardous
substances or wastes (collectively, “Hazardous Materials”) into the
environment, or otherwise relating to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands or demand letters,
injunctions, judgments, licenses, notices or notice letters, orders, permits,
plans or regulations issued, entered, promulgated or approved
thereunder.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    (ii)           Other
than those that are or were stored, used or disposed of in compliance with
applicable law, no Hazardous Materials are contained on or about any real
property currently owned, leased or used by the Company or any of its
Subsidiaries, and no Hazardous Materials were released on or about any real
property previously owned, leased or used by the Company or any of its
Subsidiaries during the period the property was owned, leased or used by the
Company or any of its Subsidiaries, except in the normal course of the Company’s
or any of its Subsidiaries’ business.

     

    (iii)           Except
as set forth in Schedule
3(s), to the best of the Company’s knowledge there are no underground
storage tanks on or under any real property owned, leased or used by the Company
or any of its Subsidiaries that are not in compliance with applicable
law.

     

    t.           Title to
Property.  The Company and its Subsidiaries have good and
marketable title in fee simple to all real property and good and marketable
title to all personal property owned by them which is material to the business
of the Company and its Subsidiaries, in each case free and clear of all liens,
encumbrances and defects except such as are described in Schedule 3(t) or such as would
not have a Material Adverse Effect.  Any real property and facilities
held under lease by the Company and its Subsidiaries are held by them under
valid, subsisting and enforceable leases with such exceptions as would not have
a Material Adverse Effect.

     

    u.           Insurance.  The
Company and each of its Subsidiaries are insured by insurers of recognized
financial responsibility against such losses and risks and in such amounts as
management of the Company believes to be prudent and customary in the businesses
in which the Company and its Subsidiaries are engaged.  Neither the
Company nor any such Subsidiary has any reason to believe that it will not be
able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse
Effect.  The Company has provided to Buyer true and correct copies of
all policies relating to directors’ and officers’ liability coverage, errors and
omissions coverage, and commercial general liability coverage.

     

    v.           Internal
Accounting Controls.  The Company and each of its Subsidiaries
maintain a system of internal accounting controls sufficient, in the judgment of
the Company’s board of directors, to provide reasonable assurance that (i)
transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability, (iii) access to
assets is permitted only in accordance with management’s general or specific
authorization and (iv) the recorded accountability for assets is compared with
the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    w.           Foreign
Corrupt Practices.  Neither the Company, nor any of its
Subsidiaries, nor any director, officer, agent, employee or other person acting
on behalf of the Company or any Subsidiary has, in the course of his actions
for, or on behalf of, the Company, used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expenses relating to
political activity; made any direct or indirect unlawful payment to any foreign
or domestic government official or employee from corporate funds; violated or is
in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977,
as amended, or made any bribe, rebate, payoff, influence payment, kickback or
other unlawful payment to any foreign or domestic government official or
employee.

     

    x.           Solvency.  The
Company (after giving effect to the transactions contemplated by this Agreement)
is solvent (i.e., its assets have
a fair market value in excess of the amount required to pay its probable
liabilities on its existing debts as they become absolute and matured) and
currently the Company has no information that would lead it to reasonably
conclude that the Company would not, after giving effect to the transaction
contemplated by this Agreement, have the ability to, nor does it intend to take
any action that would impair its ability to, pay its debts from time to time
incurred in connection therewith as such debts mature.  The Company
did receive a qualified opinion from its auditors with respect to its most
recent fiscal year end and, after giving effect to the transactions contemplated
by this Agreement, does not anticipate or know of any basis upon which its
auditors might issue a qualified opinion in respect of its current fiscal
year.

     

    y.           No
Investment Company.  The Company is not, and upon the issuance
and sale of the Securities as contemplated by this Agreement will not be an
“investment company” required to be registered under the Investment Company Act
of 1940 (an “Investment
Company”).  The Company is not controlled by an Investment
Company.

     

    z.           Certain
Registration Matters. Assuming the accuracy of the Buyers'
representations and warranties set forth in Section 3, no registration under the
Securities Act is required for the offer and sale of the Conversion Shares by
the Company to the Buyers under the transaction documents. Except as specified
in Schedule 3(z), the
Company has not granted or agreed to grant to any Person any rights (including
"piggy-back" registration rights) to have any securities of the Company
registered with the Commission or any other governmental authority that have not
been satisfied.

     

    aa.           Breach of
Representations and Warranties by the Company.  If the Company
materially breaches any of the representations or warranties set forth in this
Section 3, and in addition to any other remedies available to the Buyers
pursuant to this Agreement, the Company shall pay to the Buyer the Standard
Liquidated Damages Amount in cash or in shares of Common Stock at the option of
the Company, until such breach is cured.  If the Company elects to pay
the Standard Liquidated Damages Amounts in shares of Common Stock, such shares
shall be issued at the Conversion Price at the time of payment.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    4.           COVENANTS.

     

    a.           Best
Efforts.  The parties shall use their best efforts to satisfy
timely each of the conditions described in Section 6 and 7 of this
Agreement.

     

    b.           Form D;
Blue Sky Laws.  The Company agrees to file a Form D with
respect to the Securities as required under Regulation D and to provide a copy
thereof to each Buyer promptly after such filing.  The Company shall,
on or before the Closing Date, take such action as the Company shall reasonably
determine is necessary to qualify the Securities for sale to the Buyers at the
applicable closing pursuant to this Agreement under applicable securities or
“blue sky” laws of the states of the United States (or to obtain an exemption
from such qualification), and shall provide evidence of any such action so taken
to each Buyer on or prior to the Closing Date; provided, however, that the
Company shall not be required in connection therewith or as a condition thereto
to  qualify to do business in any jurisdiction where it would not
otherwise be required to qualify but for this Section 4(b),  subject
itself to general taxation in any such jurisdiction,  file a general
consent to service of process in any such jurisdiction,  provide any
undertakings that cause the Company undue expense or burden, or  make
any change in its charter or bylaws, which in each case the Board of Directors
of the Company determines to be contrary to the best interests of the Company
and its shareholders.

     

    c.           Reporting Status;
Eligibility to Use Form S-3 or Form S-1. The Company represents
and warrants that it meets the requirements for registration of the sale by the
Buyer of the Registrable Securities (as defined in the Registration Rights
Agreement).  So long as the Buyer beneficially owns any of the
Securities, the Company shall timely file all reports required to be filed with
the SEC pursuant to the 1934 Act, and the Company shall not terminate its status
as an issuer required to file reports under the 1934 Act even if the 1934 Act or
the rules and regulations thereunder would permit such
termination.  The Company further agrees to file all reports required
to be filed by the Company with the SEC in a timely manner so as to become
eligible, and thereafter to maintain its eligibility, for the use of Form
S-3.  The Company shall issue a press release describing the material
terms of the transaction contemplated hereby as soon as practicable following
the Closing Date but in no event more than two (2) business days of the Closing
Date, which press release shall be subject to prior review by the
Buyers.  The Company agrees that such press release shall not disclose
the name of the Buyers unless expressly consented to in writing by the Buyers or
unless required by applicable law or regulation, and then only to the extent of
such requirement.

     

    d.           Use of
Proceeds.  The Company shall use the net proceeds from the sale
of the Notes in the manner set forth in Schedule 4(d) attached hereto
and made a part hereof and shall not, directly or indirectly, use such proceeds
for (i) any loan to or investment in any other corporation, partnership,
enterprise or other person (except in connection with its currently existing
direct or indirect Subsidiaries); (ii) the satisfaction of any portion of the
Company’s debt (other than payment of trade payables and accrued expenses in the
ordinary course of the Company’s business and consistent with prior past
practices), or (iii) the redemption of any Common Stock.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    e.           Future
Offerings.  Subject to the exceptions described below, the
Company will not, without the prior written consent of a majority-in-interest of
the Buyers, which consent shall not be unreasonably withheld, negotiate or
contract with any party to obtain additional equity financing (including debt
financing with an equity component) that involves (A) the issuance of Common
Stock for cash at a discount to the market price of the Common Stock on the date
of issuance (taking into account the value of any warrants or options to acquire
Common Stock issued in connection therewith) or (B) the issuance of convertible
securities that are convertible into an indeterminate number of shares of Common
Stock or (C) the issuance of warrants during the period (the “Lock-up Period”) beginning on
the Closing Date and ending on the later of (i) two hundred seventy (270) days
from the Closing Date and (ii) one hundred eighty (180) days from the date the
Registration Statement (as defined in the Registration Rights Agreement) is
declared effective (plus any days in which sales cannot be made
thereunder).  In addition, subject to the exceptions described below,
the Company will not conduct any equity financing (including debt with an equity
component) (“Future
Offerings”) during the period beginning on the Closing Date and ending
two (2) years after the end of the Lock-up Period unless it shall have first
delivered to each Buyer, at least twenty (20) business days prior to the closing
of such Future Offering, written notice describing the proposed Future Offering,
including the terms and conditions thereof and proposed definitive documentation
to be entered into in connection therewith, and providing each Buyer an option
during the fifteen (15) day period following delivery of such notice to purchase
its pro rata share (based on the ratio that the aggregate principal amount of
Notes purchased by it hereunder bears to the aggregate principal amount of Notes
purchased hereunder) of the securities being offered in the Future Offering on
the same terms as contemplated by such Future Offering (the limitations referred
to in this sentence and the preceding sentence are collectively referred to as
the “Capital Raising
Limitations”).  In the event the terms
and conditions of a proposed Future Offering are amended in any respect after
delivery of the notice to the Buyers concerning the proposed Future Offering,
the Company shall deliver a new notice to each Buyer describing the amended
terms and conditions of the proposed Future Offering and each Buyer thereafter
shall have an option during the fifteen (15) day period following delivery of
such new notice to purchase its pro rata share of the securities being offered
on the same terms as contemplated by such proposed Future Offering, as
amended.  The foregoing sentence shall apply to successive amendments
to the terms and conditions of any proposed Future Offering.  The
Capital Raising Limitations shall not apply to any transaction involving (i)
issuances of securities in a firm commitment underwritten public offering
(excluding a continuous offering pursuant to Rule 415 under the 1933 Act, an
equity line of credit or similar financing arrangement) resulting in net
proceeds to the Company of in excess of $1,500,000, or (ii) issuances of
securities as consideration for a merger, consolidation or purchase of assets,
or in connection with any strategic partnership or joint venture (the primary
purpose of which is not to raise equity capital), or in connection with the
disposition or acquisition of a business, product or license by the
Company.  The Capital Raising Limitations also shall not apply to the
issuance of securities upon exercise or conversion of the Company’s options,
warrants or other convertible securities outstanding as of the date hereof or to
the grant of additional options or warrants, or the issuance of additional
securities, under any Company stock option or restricted stock plan approved by
the shareholders of the Company.

     

    f.           Expenses.  At
the Closing, the Company shall reimburse Buyers for expenses incurred by them in
connection with the negotiation, preparation, execution, delivery and
performance of this Agreement and the other agreements to be executed in
connection herewith (“Documents”), including,
without limitation, attorneys’ and consultants’ fees and expenses, transfer
agent fees, fees for stock quotation services, fees relating to any amendments
or modifications of the Documents or any consents or waivers of provisions in
the Documents, fees for the preparation of opinions of counsel, escrow fees, and
costs of restructuring the transactions contemplated by the
Documents.  When possible, the Company must pay these fees directly,
otherwise the Company must make immediate payment for reimbursement to the
Buyers for all fees and expenses immediately upon written notice by the Buyer or
the submission of an invoice by the Buyer.  Notwithstanding anything
herein to the contrary, the Company’s obligation to reimburse Buyers’ expenses
shall not exceed $50,000 in the aggregate.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    g.           Financial
Information.  The Company agrees to send the following reports
to each Buyer until such Buyer transfers, assigns, or sells all of the
Securities:  within ten (10) days after the filing with the SEC, a
copy of its Annual Report on Form 10-KSB or Form 10-K its Quarterly Reports on
Form 10-QSB or Form 10-Q and any Current Reports on Form 8-K;  within
one (1) day after release, copies of all press releases issued by the Company or
any of its Subsidiaries; and  contemporaneously with the making
available or giving to the shareholders of the Company, copies of any notices or
other information the Company makes available or gives to such
shareholders.

     

    h.           Authorization
and Reservation of Shares.  The Company shall at all times have
authorized, and reserved for the purpose of issuance, a sufficient number of
shares of Common Stock to provide for the full conversion or exercise of the
outstanding Notes and issuance of the Conversion Shares in connection therewith
(based on the Conversion Price of the Notes in effect from time to time) and as
otherwise required by the Notes.  The Company shall not reduce the
number of shares of Common Stock reserved for issuance upon conversion of Notes
without the consent of each Buyer.  The Company shall at all times
maintain the number of shares of Common Stock so reserved for issuance at an
amount (“Reserved
Amount”) equal to no less than two (2) times the number that is then
actually issuable upon full conversion of the Notes and Additional Notes (based
on the Conversion Price of the Notes in effect from time to time).  If
at any time the number of shares of Common Stock authorized and reserved for
issuance (“Authorized and
Reserved Shares”) is below the Reserved Amount, the Company will promptly
take all corporate action necessary to authorize and reserve a sufficient number
of shares, including, without limitation, calling a special meeting of
shareholders to authorize additional shares to meet the Company’s obligations
under this Section 4(h), in the case of an insufficient number of authorized
shares, obtain shareholder approval of an increase in such authorized number of
shares, and voting the management shares of the Company in favor of an increase
in the authorized shares of the Company to ensure that the number of authorized
shares is sufficient to meet the Reserved Amount.  If the Company
fails to obtain such shareholder approval within thirty (30) days following the
date on which the number of Reserved Amount exceeds the Authorized and Reserved
Shares, the Company shall pay to the Borrower the Standard Liquidated Damages
Amount, in cash or in shares of Common Stock at the option of the
Buyer.  If the Buyer elects to be paid the Standard Liquidated Damages
Amount in shares of Common Stock, such shares shall be issued at the Conversion
Price at the time of payment.  In order to ensure that the Company has
authorized a sufficient amount of shares to meet the Reserved Amount at all
times, the Company must deliver to the Buyer at the end of every month a list
detailing (1) the current amount of shares authorized by the Company and
reserved for the Buyer; and (2) amount of shares issuable upon conversion of the
Notes and as payment of interest accrued on the Notes for one
year.  If the Company fails to provide such list within five (5)
business days of the end of each month, the Company shall pay the Standard
Liquidated Damages Amount, in cash or in shares of Common Stock at the option of
the Buyer, until the list is delivered.  If the Buyer elects to be
paid the Standard Liquidated Damages Amount in shares of Common Stock, such
shares shall be issued at the Conversion Price at the time of
payment.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    i.           Listing.  The
Company shall promptly secure the listing of the Conversion Shares upon each
national securities exchange or automated quotation system, if any, upon which
shares of Common Stock are then listed (subject to official notice of issuance)
and, so long as any Buyer owns any of the Securities, shall maintain, so long as
any other shares of Common Stock shall be so listed, such listing of all
Conversion Shares from time to time issuable upon conversion of the
Notes.  The Company will obtain and, so long as any Buyer owns any of
the Securities, maintain the listing and trading of its Common Stock on the Pink
Sheets or any equivalent replacement exchange, the Nasdaq National Market
(“Nasdaq”), the Nasdaq
SmallCap Market (“Nasdaq
SmallCap”), the New York Stock Exchange (“NYSE”), or the American Stock
Exchange (“AMEX”) and
will comply in all respects with the Company’s reporting, filing and other
obligations under the bylaws or rules of the Financial Industry Regulatory
Authority (“FINRA”) and
such exchanges, as applicable.  The Company shall promptly provide to
each Buyer copies of any notices it receives from the Pink Sheets and any other
exchanges or quotation systems on which the Common Stock is then listed
regarding the continued eligibility of the Common Stock for listing on such
exchanges and quotation systems.

     

    j.           Corporate
Existence.  So long as a Buyer beneficially owns any Notes, the
Company shall maintain its corporate existence and shall not sell all or
substantially all of the Company’s assets, except in the event of a merger or
consolidation or sale of all or substantially all of the Company’s assets, where
the surviving or successor entity in such transaction (i) assumes the Company’s
obligations hereunder and under the agreements and instruments entered into in
connection herewith and (ii) is a publicly traded corporation whose Common Stock
is listed for trading on the Pink Sheets, Nasdaq, Nasdaq SmallCap, NYSE or
AMEX.

     

    k.           No
Integration.  The Company shall not make any offers or sales of
any security (other than the Securities) under circumstances that would require
registration of the Securities being offered or sold hereunder under the 1933
Act or cause the offering of the Securities to be integrated with any other
offering of securities by the Company for the purpose of any stockholder
approval provision applicable to the Company or its securities.

     

    l.           Restriction
on Short Sales. The Buyers agree that, so long as any of the Notes remain
outstanding, but in no event less than two (2) years from the date hereof, the
Buyers will not enter into or effect any “short sales” (as such term is defined
in Rule 3b-3 of the 1934 Act) of the Common Stock or hedging transaction which
establishes a net short position with respect to the Common Stock.

     

    m.           Breach of
Covenants.  If the Company
breaches any of the covenants set forth in this Section 4, and in addition to
any other remedies available to the Buyers pursuant to this Agreement, the
Company shall pay to the Buyers the Standard Liquidated Damages Amount, in cash
or in shares of Common Stock at the option of the Company, until such breach is
cured.  If the Company elects to pay the Standard Liquidated Damages
Amount in shares, such shares shall be issued at the Conversion Price at the
time of payment.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    5.           TRANSFER
AGENT INSTRUCTIONS.  The Company shall issue irrevocable
instructions to its transfer agent to issue certificates, registered in the name
of each Buyer or its nominee, for the Conversion Shares in such amounts as
specified from time to time by each Buyer to the Company upon conversion of the
Notes in accordance with the terms thereof (the “Irrevocable Transfer Agent
Instructions”).  Prior to registration of the Conversion Shares
under the 1933 Act or the date on which the Conversion Shares may be sold
pursuant to Rule 144 without any restriction as to the number of Securities as
of a particular date that can then be immediately sold, all such certificates
shall bear the restrictive legend specified in Section 2(g) of this
Agreement.  The Company warrants that no instruction other than the
Irrevocable Transfer Agent Instructions referred to in this Section 5, and stop
transfer instructions to give effect to Section 2(f) hereof (in the case of the
Conversion Shares, prior to registration of the Conversion Shares under the 1933
Act or the date on which the Conversion Shares may be sold pursuant to Rule 144
without any restriction as to the number of Securities as of a particular date
that can then be immediately sold), will be given by the Company to its transfer
agent and that the Securities shall otherwise be freely transferable on the
books and records of the Company as and to the extent provided in this Agreement
and the Registration Rights Agreement.  Nothing in this Section shall
affect in any way the Buyer’s obligations and agreement set forth in Section
2(g) hereof to comply with all applicable prospectus delivery requirements, if
any, upon re-sale of the Securities.  If a Buyer provides the Company
with (i) an opinion of counsel reasonably acceptable to the Company and its
counsel in form, substance and scope customary for opinions in comparable
transactions, to the effect that a public sale or transfer of such Securities
may be made without registration under the 1933 Act and such sale or transfer is
effected or (ii) the Buyer provides reasonable assurances that the Securities
can be sold pursuant to Rule 144, the Company shall permit the transfer, and, in
the case of the Conversion Shares, promptly instruct its transfer agent to issue
one or more certificates, free from restrictive legend, in such name and in such
denominations as specified by such Buyer.  The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to
the Buyers, by vitiating the intent and purpose of the transactions contemplated
hereby.  Accordingly, the Company acknowledges that the remedy at law
for a breach of its obligations under this Section 5 may be inadequate and
agrees, in the event of a breach or threatened breach by the Company of the
provisions of this Section, that the Buyers shall be entitled, in addition to
all other available remedies, to an injunction restraining any breach and
requiring immediate transfer, without the necessity of showing economic loss and
without any bond or other security being required.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    6.           CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.  The obligation of the
Company hereunder to issue and sell the Notes to a Buyer at the Closing is
subject to the satisfaction, at or before the Closing Date of each of the
following conditions thereto, provided that these conditions are for the
Company’s sole benefit and may be waived by the Company at any time in its sole
discretion:

     

    a.           The
applicable Buyer shall have executed this Agreement and the Registration Rights
Agreement, and delivered the same to the Company.

     

    b.           The
applicable Buyer shall have delivered the Purchase Price in accordance with
Section 1(b) above.

     

    c.           The
representations and warranties of the applicable Buyer shall be true and correct
in all material respects as of the date when made and as of the Closing Date as
though made at that time (except for representations and warranties that speak
as of a specific date), and the applicable Buyer shall have performed, satisfied
and complied in all material respects with the covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied
with by the applicable Buyer at or prior to the Closing Date.

     

    d.           No
litigation, statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or endorsed by or in
any court or governmental authority of competent jurisdiction or any
self-regulatory organization having authority over the matters contemplated
hereby which prohibits the consummation of any of the transactions contemplated
by this Agreement.

     

    7.           CONDITIONS
TO EACH BUYER’S OBLIGATION TO PURCHASE.  The obligation of each
Buyer hereunder to purchase the Notes at the Closing is subject to the
satisfaction, at or before the Closing Date of each of the following conditions,
provided that these conditions are for such Buyer’s sole benefit and may be
waived by such Buyer at any time in its sole discretion:

     

    a.           The
Company shall have executed this Agreement and the Registration Rights
Agreement, and delivered the same to the Buyer.

     

    b.           The
Company shall have delivered to such Buyer duly executed Notes (in such
denominations as the Buyer shall request) in accordance with Section 1(b)
above.

     

    c.           The
Irrevocable Transfer Agent Instructions, in form and substance satisfactory to a
majority-in-interest of the Buyers, shall have been delivered to and
acknowledged in writing by the Company’s Transfer Agent.

     

    d.           The
representations and warranties of the Company shall be true and correct in all
material respects as of the date when made and as of the Closing Date as though
made at such time (except for representations and warranties that speak as of a
specific date) and the Company shall have performed, satisfied and complied in
all material respects with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by the Company at or
prior to the Closing Date.  The Buyer shall have received a
certificate or certificates, executed by the chief executive officer of the
Company, dated as of the Closing Date, to the foregoing effect and as to such
other matters as may be reasonably requested by such Buyer including, but not
limited to certificates with respect to the Company’s Certificate of
Incorporation, By-laws and Board of Directors’ resolutions relating to the
transactions contemplated hereby.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    e.           No
litigation, statute, rule, regulation, executive order, decree, ruling or
injunction shall have been enacted, entered, promulgated or endorsed by or in
any court or governmental authority of competent jurisdiction or any
self-regulatory organization having authority over the matters contemplated
hereby which prohibits the consummation of any of the transactions contemplated
by this Agreement.

     

    f.           No
event shall have occurred which could reasonably be expected to have a Material
Adverse Effect on the Company.

     

    g.           The
Conversion Shares shall have been authorized for quotation on the Pink Sheets
and trading in the Common Stock on the Pink Sheets shall not have been suspended
by the SEC or the Pink Sheets.

     

    h.           The
Buyer shall have received an opinion of the Company’s counsel, dated as of the
Closing Date, in form, scope and substance reasonably satisfactory to the Buyer
and in substantially the same form as Exhibit “D” attached
hereto.

     

    i.           The
Buyer shall have received an officer’s certificate described in Section 3(c)
above, dated as of the Closing Date.

     

    8.           GOVERNING
LAW; MISCELLANEOUS.

     

    a.           Governing
Law.  THIS AGREEMENT SHALL BE ENFORCED, GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO
AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD
TO THE PRINCIPLES OF CONFLICT OF LAWS.  THE PARTIES HERETO HEREBY
SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED
IN NEW YORK, NEW YORK WITH RESPECT TO ANY DISPUTE ARISING UNDER THIS AGREEMENT,
THE AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS
CONTEMPLATED HEREBY OR THEREBY. BOTH PARTIES IRREVOCABLY WAIVE THE DEFENSE OF AN
INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH SUIT OR
PROCEEDING.  BOTH PARTIES FURTHER AGREE THAT SERVICE OF PROCESS UPON A
PARTY MAILED BY REGISTERED FIRST CLASS MAIL SHALL BE DEEMED IN EVERY RESPECT
EFFECTIVE SERVICE OF PROCESS UPON THE PARTY IN ANY SUCH SUIT OR
PROCEEDING.  NOTHING HEREIN SHALL AFFECT EITHER PARTY’S RIGHT TO SERVE
PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.  BOTH PARTIES AGREE THAT
A FINAL NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR PROCEEDING SHALL BE
CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON SUCH JUDGMENT
OR IN ANY OTHER LAWFUL MANNER.  THE PARTY WHICH DOES NOT PREVAIL IN
ANY DISPUTE ARISING UNDER THIS AGREEMENT SHALL BE RESPONSIBLE FOR ALL FEES AND
EXPENSES, INCLUDING REASONABLE ATTORNEYS’ FEES, INCURRED BY THE PREVAILING PARTY
IN CONNECTION WITH SUCH DISPUTE.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    b.           Counterparts;
Signatures by Facsimile.  This Agreement may be executed in one
or more counterparts, each of which shall be deemed an original but all of which
shall constitute one and the same agreement and shall become effective when
counterparts have been signed by each party and delivered to the other
party.  This Agreement, once executed by a party, may be delivered to
the other party hereto by facsimile transmission of a copy of this Agreement
bearing the signature of the party so delivering this Agreement.

     

    c.           Headings.  The
headings of this Agreement are for convenience of reference only and shall not
form part of, or affect the interpretation of, this Agreement.

     

    d.           Severability.  In
the event that any provision of this Agreement is invalid or unenforceable under
any applicable statute or rule of law, then such provision shall be deemed
inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law.  Any provision
hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

     

    e.           Entire
Agreement; Amendments.  This Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect
to the matters covered herein and therein and, except as specifically set forth
herein or therein, neither the Company nor the Buyer makes any representation,
warranty, covenant or undertaking with respect to such matters.  No
provision of this Agreement may be waived or amended other than by an instrument
in writing signed by the party to be charged with enforcement.

     

    f.           Notices.  Any
notices required or permitted to be given under the terms of this Agreement
shall be sent by certified or registered mail (return receipt requested) or
delivered personally or by courier (including a recognized overnight delivery
service) or by facsimile and shall be effective five days after being placed in
the mail, if mailed by regular United States mail, or upon receipt, if delivered
personally or by courier (including a recognized overnight delivery service) or
by facsimile, in each case addressed to a party.  The addresses for
such communications shall be:

     

    If to the
Company:

    

    Wellstar
International Inc.

    6911
Pilliod Road

    Holland,
OH 43528

    Attention:
Chief Executive Officer and President

    Telephone:
866-865-6460

    Facsimile:  419-867-0829

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    With a
copy to:

     

    
      Sichenzia
Ross Friedman Ference LLP

      61
Broadway, 32nd
Floor

    

    New York,
NY  10006

    Attention:   Darrin
Ocasio, Esq.

    Telephone:  (212)
930-9700

    Facsimile:   (212)
930-9725

     

    If to a
Buyer:  To the address set forth immediately below such Buyer’s name
on the signature pages hereto.

     

    With copy
to:

    

    Ballard
Spahr Andrews & Ingersoll, LLP

    1735
Market Street

    51st
Floor

    Philadelphia,
Pennsylvania  19103

    Attention:  Gerald
J. Guarcini, Esq.

    Telephone:  215-864-8625

    Facsimile:   215-864-8999

     

    Each
party shall provide notice to the other party of any change in
address.

     

    g.           Successors
and Assigns.  This Agreement shall be binding upon and inure to
the benefit of the parties and their successors and assigns.  Neither
the Company nor any Buyer shall assign this Agreement or any rights or
obligations hereunder without the prior written consent of the
other.  Notwithstanding the foregoing, subject to Section 2(f), any
Buyer may assign its rights hereunder to any person that purchases Securities in
a private transaction from a Buyer or to any of its “affiliates,” as that term
is defined under the 1934 Act, without the consent of the Company.

     

    h.           Third
Party Beneficiaries.  This Agreement is intended for the
benefit of the parties hereto and their respective permitted successors and
assigns, and is not for the benefit of, nor may any provision hereof be enforced
by, any other person.

     

    i.           Survival.  The
representations and warranties of the Company and the agreements and covenants
set forth in Sections 3, 4, 5 and 8 shall survive the closing hereunder
notwithstanding any due diligence investigation conducted by or on behalf of the
Buyers.  The Company agrees to indemnify and hold harmless each of the
Buyers and all their officers, directors, employees and agents for loss or
damage arising as a result of or related to any breach or alleged breach by the
Company of any of its representations, warranties and covenants set forth in
Sections 3 and 4 hereof or any of its covenants and obligations under this
Agreement or the Registration Rights Agreement, including advancement of
expenses as they are incurred.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    j.           Publicity.  The
Company and each of the Buyers shall have the right to review a reasonable
period of time before issuance of any press releases, SEC, Pink Sheets or FINRA
filings, or any other public statements with respect to the transactions
contemplated hereby; provided, however, that the
Company shall be entitled, without the prior approval of each of the Buyers, to
make any press release or SEC, Pink Sheets (or other applicable trading market)
or FINRA filings with respect to such transactions as is required by applicable
law and regulations (although each of the Buyers shall be consulted by the
Company in connection with any such press release prior to its release and shall
be provided with a copy thereof and be given an opportunity to comment
thereon).

     

    k.           Further
Assurances.  Each party shall do and perform, or cause to be
done and performed, all such further acts and things, and shall execute and
deliver all such other agreements, certificates, instruments and documents, as
the other party may reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation of the
transactions contemplated hereby.

     

    l.           No Strict
Construction.  The language used in this Agreement will be
deemed to be the language chosen by the parties to express their mutual intent,
and no rules of strict construction will be applied against any
party.

     

    m.           Remedies.  The
Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Buyers by vitiating the intent and purpose of the
transaction contemplated hereby.  Accordingly, the Company
acknowledges that the remedy at law for a breach of its obligations under this
Agreement will be inadequate and agrees, in the event of a breach or threatened
breach by the Company of the provisions of this Agreement, that the Buyers shall
be entitled, in addition to all other available remedies at law or in equity,
and in addition to the penalties assessable herein, to an injunction or
injunctions restraining, preventing or curing any breach of this Agreement and
to enforce specifically the terms and provisions hereof, without the necessity
of showing economic loss and without any bond or other security being
required.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, the
undersigned Buyers and the Company have caused this Agreement to be duly
executed as of the date first above written.

     

    WELLSTAR
INTERNATIONAL INC.

    

    /s/ John
Antonio

    John
Antonio

    Chief
Executive Officer

     

    AJW
PARTNERS, LLC

    By:  SMS
Group, LLC

     

    /s/ Corey
S. Ribotsky

    Corey S.
Ribotsky

    Manager

    

    
      	
              RESIDENCE:

            	
              Delaware

            

    

    

    
      	
              ADDRESS: 

            	
              1044
      Northern Boulevard

            

    

    Suite 302

    Roslyn, New York 11576

    Facsimile:  (516)
739-7115

    Telephone:  (516)
739-7110

    

    AGGREGATE
SUBSCRIPTION AMOUNT:

    

    
      
        
          
            	
                    Aggregate
      Principal Amount of Notes:

                  	 	$	254.40	 

          

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    AJW
PARTNERS II, LLC

    By:  SMS
Group, LLC

     

    /s/ Corey
S. Ribotsky

    Corey S.
Ribotsky

    Manager

    

    
      	
              RESIDENCE: 

            	
              Delaware

            

    

    

    
      	
              ADDRESS: 

            	
              1044
      Northern Boulevard

            

    

    Suite 302

    Roslyn, New York 11576

    Facsimile:   (516)
739-7115

    Telephone:  (516)
739-7110

    

    AGGREGATE
SUBSCRIPTION AMOUNT:

    

    
      
        
          
            	
                    Aggregate
      Principal Amount of Notes:

                  	 	$	6,336.15	 

          

        

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    AJW
MASTER FUND, LTD.

    By:  First
Street Manager II, LLC

     

    /s/ Corey
S. Ribotsky

    Corey S.
Ribotsky

    Manager

     

    
      	
              RESIDENCE: 

            	
                  Cayman
      Islands

            

    

    

    
      	
              ADDRESS: 

            	
              AJW
      Offshore, Ltd.

            

    

    P.O. Box
32021 SMB

    Grand
Cayman, Cayman Island, B.W.I.

    

    AGGREGATE
SUBSCRIPTION AMOUNT:

    

    
      
        
          
            	
                    Aggregate
      Principal Amount of Notes:

                  	 	$	8,546.25	 

          

        

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    AJW
MASTER FUND II, LTD.

    By:  First
Street Manager II, LLC

    

    /s/ Corey
S. Ribotsky

    Corey S.
Ribotsky

    Manager

    

    
      	
              RESIDENCE: 

            	
                  Cayman
      Islands

            

    

    

    
      	
              ADDRESS: 

            	
              AJW
      Offshore, Ltd.

            

    

    P.O. Box
32021 SMB

    Grand
Cayman, Cayman Island, B.W.I.

    

    AGGREGATE
SUBSCRIPTION AMOUNT:

    

    
      
        
          
            	
                    Aggregate
      Principal Amount of Notes:

                  	 	$	62,526.75	 

          

        

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    NEW
MILLENNIUM CAPITAL PARTNERS III, LLC

    By:  First
Street Manager II, LLP

     

    /s/ Corey
S. Ribotsky

    Corey S.
Ribotsky

    Manager

    

    
      	
              RESIDENCE: 

            	
                  New
      York

            

    

    

    
      	
              ADDRESS: 

            	
              1044
      Northern Boulevard

            

    

    Suite 302

    Roslyn, New York 11576

    Facsimile:       (516)
739-7115

    Telephone:     
(516) 739-7110

    

    AGGREGATE
SUBSCRIPTION AMOUNT:

    

    
      
        
          
            	
                    Aggregate
      Principal Amount of Notes:

                  	 	$	1,836.45

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]